+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


World Biosimilars/Follow-on-Biologics Market - Opportunities and Forecasts, 2014 - 2020

  • ID: 3447752
  • Report
  • September 2015
  • Region: Global
  • 120 pages
  • Allied Analytics LLP

Enquire about COVID-19 updates for this product.

Enquire Now
Global Biosimilars Market to Grow at an Impressive CAGR of 49.1% During 2015-2020


  • Biocon
  • Biogen idec Inc.
  • Celltrion
  • Genentech (Roche Group)
  • Hospira
  • LG Life Sciences
Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. The development of biosimilars and validation with reference biologics play a significant role in the commercialization of biosimilars. Economic pricing of biosimilars, ease in development and a quick approval process are some key driving factors that drive the growth of this market. Effective and timely formulated regulations facilitate the viability and balance between original and biosimilar products. Moreover, a favorable regulatory environment and the establishment of IPR protections are factors that boost the market growth. The upcoming patent expiration for blockbuster drugs has revolutionized the aspect of commercialization whilst triggering a large scale adoption of biosimilars. Biosimilars industry is facing problems relating to production efficiency and quantity. The lack of economies of scale for small scale manufacturers and absence of regulatory guidelines in lucrative regions such as China, US are hindering the growth of biosimilars market. However, strong government initiatives pertaining to production and approval is a key factor that would eventually reduce the impact of these restraints over the forecast period. Global biosimilars/follow-on-biologics market accounted for an overall revenue of $2,552.0 million in 2014 and it is estimated to generate an approximate revenue of $26,551.3 million by 2020, registering a CAGR of 49.1% from 2015 to 2020.

The product segment in the biosimilars market comprises of Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Colony Stimulating Factors and others. Biosimilars erythropoietin is the highest revenue generating biosimilars drug candidate owing to its high approval rate for commercialization. Interferon biosimilars are the fastest growing drugs in the biosimilars market. This growth is supplemented by the use of interferon biosimilars across a wide range of applications.

The biosimilars applications market is segmented into blood disorders, oncology diseases, chronic and autoimmune diseases and growth hormone deficiency. The application of biosimilars in blood disease treatment is the highest revenue generating segment owing to the high-priced reference biologics and frequent application. However, biosimilars applications in autoimmune and chronic diseases exhibit the highest potential due to the changing off patent scenario.

Based on geography, the biosimilars market is segmented across North America, Europe, Asia-Pacific and LAMEA. Asia Pacific and LAMEA exhibit a large scale demand for biosimilars due to the growing prevalence of chronic diseases in these regions. Collaboration with local players is a key opportunity for biosimilars in developing economies. Many companies such as, Amgen and Novartis are collaborating with Asian players to reach to the depth of the biopharmaceutical market. The absence of effective regulatory guidelines for product approval and commercialization limit the growth of the biosimilars market in North America. However, recent draft published by US FDA has approved first biosimilar in United States. This would eventually standardized the procedure of approval and commercialization of biosimilars in United States.

This report provides a comprehensive market share analysis of leading companies and highlights the competition in the market. Product launch is the key strategy adopted by the leading player of biosimilars industry. The key companies profiled in this report are Novartis (Sandoz), Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec, Inc., and Genentech (Roche Group).

- This report provides a detailed analysis of drivers and factors that limit the market expansion
- The report provides a financial market forecast for the next eight years by considering the 2014 as the base year for evaluation.
- Comprehensive and quantitative data about changing market trends, competition and opportunities in biosimilars market are provided in the report
- Use of Porters Five Forces model and SWOT analysis would help stakeholders in making strategic decisions
- Deep dive analysis of leading market players and their key strategies, helps in better understanding the market dynamics
- Identification of key investment pockets in the biosimilars market would help the stakeholders in making informed decisions

Key Deliverables

Global biosimilars/follow-on-biologics market is categorized into product types, applications and geography.

- Human growth hormone
- Erythropoietin
- Monoclonal antibodies
- Insulin
- Interferon
- Granulocyte-Colony Stimulating Factor
- Peptide
- Others

- Blood disorders
- Oncology diseases
- Chronic and autoimmune diseases
- Growth hormone deficiencies
- Others

- North America
- Europe
- Asia-Pacific

Note: Product cover images may vary from those shown


  • Biocon
  • Biogen idec Inc.
  • Celltrion
  • Genentech (Roche Group)
  • Hospira
  • LG Life Sciences

1.1 Key Benefits
1.2 Key Market Segment
1.3 Research Methodology

1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Analyst tools and models


2.1 CXO perspective
2.2 Market beyond: what to expect by 2025

2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario


3.1 Market Definition
3.2 Diverse approach of global regulators towards biosimilars
3.3 Safety issues of biosimilar drugs
3.4 Key Findings

3.4.1 Top impacting factors
3.4.2 Top winning strategies
3.4.3 Top investment pockets

3.5 Regulation and Reimbursement scenario

3.5.1 Regulations in United States
3.5.2 Regulations in Europe
3.5.3 Regulation in Asia
3.5.4 Comparison of Biosimilar medicine guidelines

3.6 Emerging economies a hotspot for biosimilars market

3.6.1 Brazil a treasure for the biosimilar manufacturers
3.6.2 China the bulkmarket for biosimilars
3.6.3 India an early adopter of biosimilars

3.7 Porters five force analysis

3.7.1 Higher bargaining of suppliers
3.7.2 Moderate bargaining power of buyers
3.7.3 Higher threats from substitutes due to lower switching cost
3.7.4 Lower threats from new entrants due to technological and political barriers
3.7.5 Higher competition among players

3.8 Value chain analysis

3.8.1 Primary activities
3.8.2 Supportive activities

3.9 Clinical trials

3.9.1 MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia
3.9.2 Efficacy Study of Two Formulations of Erythropoietin
3.9.3 Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anemia in Hematology and Oncology
3.9.4 An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1

3.10 Market Share analysis, 2014
3.11 Market Dynamics

3.11.1 Drivers Growing pressure to reduce healthcare expenditure Various blockbusters going off patent High prevalence of chronic diseases among ageing population Favorable intervention from the developing economies Lower cost biosimilars drugs than original biologics

3.11.2 Restraints High initial investment in research and development Stringent regulations in developed economies to restrict investment Medical Efficacy and Patient Safety

3.11.3 Opportunities opportunities in Emerging economies Emergence of bio-betters drugs


4.1 Monoclonal Antibodies (MAb) Technology

4.1.1 Drivers

4.2 Recombinant DNA Technology (rDNA technology)

4.2.1 Drivers
4.2.2 Restraints & Opportunities

4.3 Chromatography

4.3.1 Protein sequencing
4.3.2 Liquid chromatography (LC)
4.3.3 Gas Chromatography (GC)
4.3.4 Drivers

4.4 Nuclear magnetic resonance (NMR) technology

4.4.1 Drivers

4.5 Electrophoresis

4.5.1 Drivers
4.5.2 Restraints & Opportunities
4.5.3 Gel Electrophoresis
4.5.4 Capillary Electrophoresis


4.6.1 Drivers
4.6.2 Restraints

4.7 Western Blotting

4.7.1 Drivers

4.8 Bioassay

4.8.1 Drivers
4.8.2 Restraints
4.8.3 Techniques in Bioassay


5.1 Human Growth Hormone

5.1.1 Key market trends
5.1.2 Key growth factors and opportunities
5.1.3 Market size & forecast

5.2 Insulin

5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size & forecast

5.3 Interferon

5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size & forecast

5.4 Granulocyte colony stimulating factor (G-CSF)

5.4.1 Key market trends
5.4.2 Key growth factors and opporunities
5.4.3 Market size & forecast

5.5 Erythropoietin

5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size & forecast

5.6 Monoclonal antibodies

5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size & forecast

5.7 Peptides
5.8 Others

5.8.1 Key market trends
5.8.2 Key growth factors and opportunity


6.1 Blood disorders

6.1.1 Drivers
6.1.2 Chemotherapy induce Anaemia Drivers RESTRAIN AND OPPORTINITIES

6.1.3 Hemophilia
6.1.4 Pulmonary embolism DRIVER

6.2 Oncology diseases

6.2.1 Driver
6.2.2 Opportunities and restraints
6.2.3 Lungs cancer
6.2.4 Breast cancer
6.2.5 Cervical cancer
6.2.6 Colorectal cancer
6.2.7 Prostate cancer
6.2.8 Leukaemia

6.3 Chronic and autoimmune diseases

6.3.1 Diabetes Drivers

6.3.2 Neutropenia
6.3.3 Multiple sclerosis Drivers Restraints and opportunities

6.3.4 Cystic Fibrosis
6.3.5 Rheumatoid arthritis (RA) Drivers Restraints

6.3.6 Acromegaly drivers

6.3.7 Leprosy

6.4 Growth hormone deficiency

6.4.1 Drivers

6.5 Others

6.5.1 Gaucher disease
6.5.2 Osteoporosis


7.1 Contract Research and Manufacturing Services

7.1.1 Drivers
7.1.2 Restraints & Opportunities

7.2 Clinical trials

7.2.1 Drivers & Restraints
7.2.2 Phase I
7.2.3 Phase II
7.2.4 Phase III


8.1 North America

8.1.1 Key market trends
8.1.2 Key growth factors and opportunities
8.1.3 Market size & forecast

8.2 Europe

8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size & forecast

8.3 Asia-Pacific


8.3.2 Key growth factors and opporunities
8.3.3 Market size & forecast


8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size & forecast


9.1 US

9.1.1 Hospira Recent Activities

9.2 Europe

9.2.1 Stada Arzneimittel AG Recent Activities

9.2.2 Hexal AG
9.2.3 Ratiopharm GmbH
9.2.4 Bioton Recent Activities

9.2.5 Sandoz GmbH Recent Activities

9.3 India

9.3.1 Dr.Reddy's Labs (DRL) Recent Activities

9.3.2 Intas Pharmaceuticals Ltd. Recent Activities

9.3.3 Wockhardt Limited Recent Activities

9.3.4 Biocon Limited Recent Activities

9.3.5 Shantha Biotechnics Limited Recent Activities

9.3.6 Reliance Life Sciences

9.4 Korea

9.4.1 Dong-A Pharmaceutical Co., Ltd Recent Activities

9.4.2 LG Life Sciences Recent Activities

9.4.3 Celltrion Pharm, Inc. Recent Activities

9.5 Others

9.5.1 Teva Pharmaceutical Industries Ltd. Recent Activities


10.1 Novartis (Sandoz)

10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segment overview
10.1.4 Business performance
10.1.5 Key strategies Primary Strategies: Clinical Trials secondary Strategies: approval

10.1.6 SWOT analysis

10.2 Synthon Pharmaceuticals, Inc.

10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segment overview
10.2.4 Key strategies Primary Strategies: agreement secondary Strategies: clinical trials

10.2.5 SWOT analysis

10.3 Teva Pharmaceutical Industries Ltd.

10.3.1 Company Overview
10.3.2 Company Snapshot
10.3.3 Operating business segment overview
10.3.4 Business performance
10.3.5 Key strategies Primary Strategies: approval secondary Strategies: clinical trials

10.3.6 SWOT analysis

10.4 LG Life Sciences

10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segment overview
10.4.4 Business performance
10.4.5 Key strategies Primary Strategies: Collaboration

10.4.6 SWOT analysis

10.5 Celltrion

10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segment overview
10.5.4 Business Performance
10.5.5 Key strategies Primary Strategies: approval

10.5.6 SWOT analysis

10.6 Biocon

10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segment overview
10.6.4 Business Performance
10.6.5 Key strategies Primary Strategy: product launch secondary Strategy: clinical trial

10.6.6 SWOT analysis

10.7 Hospira

10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segment overview
10.7.4 Business performance
10.7.5 Key strategies Primary Strategies: approval secondary Strategies: clinical trials

10.7.6 SWOT analysis

10.8 Merck Serono (Merck Group)

10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segment overview
10.8.4 Business performance
10.8.5 Key strategies Primary Strategies: partnership and product launch

10.8.6 SWOT analysis

10.9 Biogen idec Inc.

10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segment overview
10.9.4 Business performance
10.9.5 Key strategies Primary Strategies: agreement and joint venture

10.9.6 SWOT analysis

10.10 Genentech (Roche Group)

10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segment overview
10.10.4 Key strategies Primary Strategies: Investment and license

10.10.5 SWOT analysis

List of Figures
Fig. 1 Impact Analysis Of Moderate Growth Scenario (2020-2025)
Fig. 2 Impact Analysis Of Rapid Growth Scenario (2020-2025)
Fig. 3 Impact Analysis Of Diminishing Growth Scenario (2020-2025)
Fig. 4 Biosimilar Pipeline Analysis By Companies (2015)
Fig. 5 Biosimilar Pipeline Analysis By Development Phase (2015)
Fig. 6 Biosimilar Pipeline Development Analysis By Company (2015)
Fig. 7 Top Factors Impacting Biosimilars Market (2014-2020)
Fig. 8 Top Wining Strategies For Biosimilars Market During (2010-2015)
Fig. 9 Top Wining Strategies By Subtype Of Developments (2010-2015)
Fig. 10 Top Investment Pockets Of Biosimilars/Follow-On-Biologics Market Products, 2014-202
Fig. 11 Key Achievements For Biosimilar Regulators (2010)
Fig. 12 Regulatory Framework For Biosimilar Products In China
Fig. 13 Porter’S Five Forces Analysis Of Biosimilars Market
Fig. 14 Value Chain Analysis Of Biosimilars Market
Fig. 15 Impact Analysis Of Stakeholders Involved In Primary Activities (2014-2020)
Fig. 16 Market Share Analysis Of Biosimilars Market (2014)
Fig. 17 Impact Analysis Of Product Market Segments (2014, 2020-2025)
Fig. 18 Number Of Incidences Of Diabetes Globally, By Geography (2000, 2011 & 2030)
Fig. 19 Impact Analysis Of Application Market Segments (2014-2020-2025)
Fig. 20 Impact Of Regulation On Various Geographies, 2013
Fig. 21 Novartis Net Revenue Generation By Geography (2014)
Fig. 22 Novartis Net Revenue Generation By Businesses (2014)
Fig. 23 SWOT Analysis Of Novartis (Sandoz)
Fig. 24 SWOT Analysis Of Synthon Pharmaceuticals
Fig. 25 Net Revenue Generation By Geography (2014)
Fig. 26 Net Revenue Generation By Businesses (2014)
Fig. 27 SWOT Analysis Of Teva Pharmaceutical Industries Ltd.
Fig. 28 Net Revenue Generation (2011-2013)
Fig. 29 SWOT Analysis Of Lg Life Sciences
Fig. 30 Net Revenue During 2012-2014 ($Million)
Fig. 31 SWOT Analysis Of Celltrion
Fig. 32 Revenue Generated By Business Units (2013)
Fig. 33 SWOT Analysis Of Biocon
Fig. 34 Net Sales By Geography (2014)
Fig. 35 Net Sales By Business Units (2014)
Fig. 36 SWOT Analysis Of Hospira
Fig. 37 Net Sales By Geography (2014)
Fig. 38 Net Sales By Business Units (2014)
Fig. 39 SWOT Analysis Of Merck Serono
Fig. 40 Net Sales By Geography (2014)
Fig. 41 Net Sales By Principle Products (2014)
Fig. 42 SWOT Analysis Of Biogen Idec Inc.
Fig. 43 SWOT Analysis Of Genentech

List of Tables
Table 1 Global Biosimilars Moderate Growth Scenario Market By Geography, 2020-2025 ($Million)
Table 2 Global Biosimilars Rapid Growth Scenario Market By Geography, 2020-2025 ($Million)
Table 3 Global Biosimilars Diminishing Growth Scenario Market By Geography, 2020-2025 ($Million)
Table 4 Biosimilars Guidelines Adopted By Regions
Table 5 Comparison Of Biosimilar Medicine Guidelines By Geography (2013)
Table 6 Biosimilars Development 2013 (Latin America)
Table 7 Off Going Patents 2013-201
Table 8 Prevalence Of Top Two Chronic Diseases (2013)
Table 9 Biosimilar Development Status (2013)
Table 10 Global Biosimilars/Follow-On-Biologics Market, By Product Types 2014-2020 ($Million)
Table 11 Patents Status For The Human Growth Hormone (Biologics)
Table 12 Patent Expiration Status For Human Growth Hormone During 2014-2020 (Biologics)
Table 13 Global Hgh Biosimilars/Follow-On-Biologics Market, By Geography 2014-2020 ($Million)
Table 14 Patents Approved For Insulin (Biologics)
Table 15 Global Insulin Biosimilars/Follow-On-Biologics Market, By Geography, 2014-2020 ($Million)
Table 16 Patents Approved For Interferon (Biologics)
Table 17 Patent Expiration Status For Interferon During, 2014-2020 (Biologics)
Table 18 Global Interferon Biosimilars/Follow-On-Biologics Market, By Geography, 2014-2020 ($Million)
Table 19 Patent Expiration Status For G-Csf Biosimilars During, 2014-2020 (Biologics)
Table 20 Global G-Csf Biosimilars/Follow-On-Biologics Market, By Geography, 2014-2020 ($Million)
Table 21 Patents Status For Erythropoietin (Biologics)
Table 22 Patent Expiration Status For Erythropoietin During 2014-2020 (Biologics)
Table 23 Global Erythropoietin Biosimilars/Follow-On-Biologics Market, By Geography, 2014-2020 ($Million)
Table 24 Drug Patent Expiration For Monoclonal Antibodies (Biologics)
Table 25 Patent Expiration Status For Monoclonal Antibodies During 2014-2020 (Biologics)
Table 26 Global Mab Biosimilars/Follow-On-Biologics Market, By Geography, 2014-2020 ($Million)
Table 27 Global Peptide Biosimilars/Follow-On-Biologics Market, By Geography, 2014-2020 ($Million)
Table 28 Hirudin Biosimilar Candidate Status
Table 29 Global Other Biosimilars/Follow-On-Biologics Market, By Geography 2014-2020 ($Million)
Table 30 Global Biosimilars/Follow-On-Biologics Market, By Applications, 2014-2020 ($Million)
Table 31 Global Blood Disorders Biosimilars/Follow-On-Biologics Market, By Geography, 2014-2020 ($Million)
Table 32 Global Oncology Disorder Biosimilars/Follow-On-Biologics Market, By Geography, 2014-2020 ($Million)
Table 33 Global Chronic And Autoimmune Disorder Biosimilars/Follow-On-Biologics Market, By Geography, 2014-2020 ($Million)
Table 34 Global Growth Hormone Deficiency Disorder Biosimilars/Follow-On-Biologics Market, By Geography, 2014-2020, ($Million)
Table 35 Global Other Disorders Biosimilars/Follow-On-Biologics Market, By Geography 2014-2020 ($Million)
Table 36 Global Biosimilars/Follow-On-Biologics Market, By Geography 2014-2020 ($Million)
Table 37 North America Biosimilars/Follow-On-Biologics Market, By Application, 2014-2020 ($Million)
Table 38 Biosimilars Commercially Available In European Union
Table 39 Europe Biosimilars/Follow-On-Biologics Market, By Applications, 2014-2020 ($Million)
Table 40 Asia-Pacific Biosimilars/Follow-On-Biologics Market, By Applications, 2014-2020 ($Million)
Table 41 Lamea Biosimilars/Follow-On-Biologics Market, By Applications, 2014-2020 ($Million)

Note: Product cover images may vary from those shown



  • Biocon
  • Biogen idec Inc.
  • Celltrion
  • Genentech (Roche Group)
  • Hospira
  • LG Life Sciences
According to the new report titled, “World Biosimilars/Follow-On-Biologics – Market Opportunities, and Forecast, 2014-2020", the global Biosimilars/Follow-On-Biologics market is projected to grow at a CAGR of 49.1% from 2015 to 2020. Europe would continue to dominate the market while Asia Pacific would emerge as fastest growing region over the forecast period.

Recent approval of Zarxio (filgrastim-sndz) as first biosimilar by U.S. FDA has opened new opportunities for biosimilar manufactures. Patents for number of blockbuster bio-pharmaceuticals have either expired or are on the verge of expiration, which is majorly driving the growth of biosimilars industry. Changes in regulatory guidelines and convenient biosimilar drug approval processes have a major impact on the commercial growth of global biosimilars market. However, the high investment associated with research and development, longer development processes and requirements of economies of scale for profitability largely limit the growth of biosimilars market. The integration of developmental plan with regulatory guidelines and the adoption of optimal commercial strategies would play crucial role in commercial growth of biosimilars market.

Glycosylated proteins namely, erythropoietin and monoclonal antibodies are the leading biosimilar segments commercially available across the globe, together accounting for about one-third of the market revenue in 2014. This significant hold in the market is chiefly due to its large application in the treatment of chronic conditions such as blood related disorders, cancer, among others.

Key findings of the study:
- The biosimilar applications in blood disorders and oncology collectively evaluated at 61% in 2014
- Interferon is fastest growing biosimilar, expected to grow at a CAGR of 51.1% during the forecast period
- U.S. would find space in biosimilar market with single-digit revenue share of overall biosimilar market by 2020

European region is the leading beneficiary of biosimilars market and is attracting investors, interested in biosimilars industry. The prospects in the European region are largely supplemented by the presence of streamlined regulatory guidelines and a high level of adoption for biosimilars among physicians. The establishment of favourable regulations such as Article 10(4) of Directive 2001/83/EC by the European Medical Association (EMA) has clarified the clinical aspect of biosimilars. This standard set by EMA has attracted investors to invest into the development of biosimilars. The Asia-Pacific region projects the fastest growth rate, supplemented by the high prevalence of chronic diseases and the growing demand for economic bio-pharmaceuticals. The commercial scenario of biosimilars in North America is bleak due to the absence of regulations for approval and commercialization. However, after the launch of the first biosimilar in United States, the investors are now focusing on this region to boost their pro

The commercialization of filgrastim biosimilars in the United States have bring the revolutionary changes in development of biosimilars. Pharmaceutical companies interested in investing into biosimilars market are now focusing on the agreement and acquisitions, in order to expand their presence in biosimilars market. Recently, the Pfizer has acquired Hospira, a global leader in biosimilars. This acquisition has strengthen the biosimilar portfolio of Pfizer. Also, it increase the global reach of Hospira through commercial capabilities, scientific expertise of Pfizer.
Note: Product cover images may vary from those shown
- Biocon
- Biogen idec Inc.
- Celltrion
- Genentech (Roche Group)
- Hospira
- LG Life Sciences
- Merck Serono (Merck Group)
- Novartis (Sandoz)
- Synthon Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.

Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.